{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:07:46Z","timestamp":1787836066415,"version":"build-2784847793"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the rescue treatment proposed to patients with refractory cardiogenic shock. The VA-ECMO implantation promotes inflammation and ischemia-reperfusion injuries through the VA-ECMO flow, causing digestive mucosa barrier disrupture and inducing translocation of bacterial wall components\u2014Lipopolysaccharides (LPS) with further inflammation and circulatory impairment. LPS is a well-studied surrogate indicator of bacterial translocation. Oxiris membrane is a promising and well-tolerated device that can specifically remove LPS. The main study aim is to compare the LPS elimination capacity of Oxiris membrane vs. a non-absorbant classical renal replacement (RRT) membrane in patients with cardiogenic shock requiring VA-ECMO.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> ECMORIX is a randomized, prospective, single-center, single-blind, parallel-group, controlled study. It compares the treatment with Oxiris membrane vs. the standard continuous renal replacement therapy care in patients with cardiogenic shock support by peripheral VA-ECMO. Forty patients will be enrolled in both treatment groups. The primary endpoint is the value of LPS serum levels after 24 h of treatment. LPS serum levels will be monitored during the first 72 h of treatment, as clinical and cardiac ultrasound parameters, biological markers of inflammation and 30-day mortality.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Oxiris membrane appears to be beneficial in controlling the VA-ECMO-induced ischemia-reperfusion inflammation by LPS removal. ECMORIX results will be of major importance in the management of severe cases requiring VA-ECMO and will bring pathophysiological insights about the LPS role in this context.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>www.ClinicalTrials.gov<\/jats:ext-link>, identifier: NCT04886180.<\/jats:p>","DOI":"10.3389\/fcvm.2021.738496","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T10:02:02Z","timestamp":1644919322000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Single-Blind, Randomized Controlled Trial"],"prefix":"10.3389","volume":"8","author":[{"given":"Stefan","family":"Andrei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Berthoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Catherine","family":"Morgant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belaid","family":"Bouhemad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Gr\u00e9goire","family":"Guinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The ECMORIX Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e011991","DOI":"10.1161\/JAHA.119.011991","article-title":"Cardiogenic shock","volume":"8","author":"Vahdatpour","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e000590","DOI":"10.1161\/JAHA.113.000590","article-title":"Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States","volume":"3","author":"Kolte","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00392-007-0626-5","article-title":"Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock","volume":"97","author":"Debrunner","year":"2008","journal-title":"Clin Res Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00063-012-0117-y","article-title":"Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-\u03b3, TNF-\u03b1, MIP-1\u03b2, G-CSF, and MCP-1\u03b2","volume":"107","author":"Prondzinsky","year":"2012","journal-title":"Medizinische Klinik Intensivmedizin Notfallmedizin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e006956","DOI":"10.1161\/CIRCOUTCOMES.120.006956","article-title":"Systemic inflammatory response syndrome is associated with increased mortality across the spectrum of shock severity in cardiac intensive care patients","volume":"13","author":"Jentzer","year":"2020","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13054-016-1570-4","article-title":"The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology","volume":"20","author":"Millar","year":"2016","journal-title":"Crit Care."},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40635-019-0249-y","article-title":"Extracorporeal life support and systemic inflammation","volume":"7","author":"Al-Fares","year":"2019","journal-title":"Intens Care Med Exp."},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13054-016-1458-3","article-title":"The digestive tract as the origin of systemic inflammation","volume":"20","author":"de Jong","year":"2016","journal-title":"Crit Care."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0167-5273(99)00118-7","article-title":"Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation","volume":"72","author":"Brunkhorst","year":"1999","journal-title":"Int J Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1203\/PDR.0b013e3181e4c9f8","article-title":"Extracorporeal membrane oxygenation causes loss of intestinal epithelial barrier in the newborn piglet","volume":"68","author":"Kurundkar","year":"2010","journal-title":"Pediatr Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/labinvest.2009.119","article-title":"Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine","volume":"90","author":"McILwain","year":"2010","journal-title":"Lab Investig."},{"key":"B13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/labinvest.2013.149","article-title":"Intestinal epithelial apoptosis initiates gut mucosal injury during extracorporeal membrane oxygenation in the newborn piglet","volume":"94","author":"MohanKumar","year":"2014","journal-title":"Lab Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40168-018-0441-4","article-title":"Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction","volume":"6","author":"Zhou","year":"2018","journal-title":"Microbiome."},{"key":"B15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2008.01.006","article-title":"LPS\/TLR4 signal transduction pathway","volume":"42","author":"Lu","year":"2008","journal-title":"Cytokine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40635-018-0177-2","article-title":"In vitro comparison of the adsorption of inflammatory mediators by blood purification devices","volume":"6","author":"Malard","year":"2018","journal-title":"Intens Care Med Exp."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0220444","DOI":"10.1371\/journal.pone.0220444","article-title":"Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study","volume":"14","author":"Broman","year":"2019","journal-title":"PLoS ONE."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1002\/ehf2.13427","article-title":"Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial","volume":"8","author":"Ellouze","year":"2021","journal-title":"ESC Heart Failure"},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0267659118791072","article-title":"Extubation of patients undergoing extracorporeal life support. A retrospective study","volume":"34","author":"Ellouze","year":"2019","journal-title":"Perfusion."},{"key":"B20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00134-016-4665-0","article-title":"Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines","volume":"43","author":"Reintam Blaser","year":"2017","journal-title":"Intens Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"155182","DOI":"10.1016\/j.cyto.2020.155182","article-title":"Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass","volume":"133","author":"Nguyen","year":"2020","journal-title":"Cytokine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000500015","article-title":"Rationale of hemoadsorption during extracorporeal membrane oxygenation support","volume":"48","author":"Napp","year":"2019","journal-title":"Blood Purif."},{"key":"B23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000502540","article-title":"Changes in cytokines, haemodynamics and microcirculation in patients with sepsis\/septic shock undergoing continuous renal replacement therapy and blood purification with cytosorb","volume":"49","author":"Zuccari","year":"2020","journal-title":"Blood Purif."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e13044","DOI":"10.1097\/MD.0000000000013044","article-title":"Pancreatitis cytosorbents (CytoSorb) inflammatory cytokine removal: a prospective study (PACIFIC)","volume":"98","author":"Huber","year":"2019","journal-title":"Medicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13054-021-03468-x","article-title":"Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis","volume":"25","author":"Scharf","year":"2021","journal-title":"Crit Care."},{"key":"B26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0391398820981383","article-title":"Haemoadsorption by CytoSorb\u00ae in patients with acute liver failure: a case series","volume":"44","author":"Tomescu","year":"2020","journal-title":"Int J Artif Organs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/pcmedi\/pbab005","article-title":"Blood purification for sepsis: an overview","volume":"4","author":"Zhang","year":"2021","journal-title":"Precis Clin Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499786","article-title":"Extracorporeal blood purification therapies for sepsis","volume":"47","author":"Monard","year":"2019","journal-title":"Blood Purif."},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000502680","article-title":"Cytokine removal in extracorporeal blood purification: an in vitro study","volume":"49","author":"Harm","year":"2020","journal-title":"Blood Purif."},{"key":"B30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13054-019-2399-4","article-title":"Cytokine clearance with CytoSorb\u00ae during cardiac surgery: a pilot randomized controlled trial","volume":"23","author":"Poli","year":"2019","journal-title":"Crit Care."},{"key":"B31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-2600(21)00177-6","article-title":"Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial","volume":"9","author":"Supady","year":"2021","journal-title":"Lancet Respirat Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499589","article-title":"Continuous renal replacement therapy with the adsorbing filter oxiris in septic patients: a case series","volume":"47","author":"Turani","year":"2019","journal-title":"Blood Purif."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/aor.13786","article-title":"The absorbing filter Oxiris in severe coronavirus disease 2019 patients: a case series","volume":"44","author":"Zhang","year":"2020","journal-title":"Artif Organs."},{"key":"B34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1159\/000511724","article-title":"Continuous renal replacement therapy with oXiris\u00ae membrane in severe ebstein-barr virus-mediated hemophagocytic lymphohistiocytosis: a case report","volume":"50","author":"Samman","year":"2020","journal-title":"Blood Purif."},{"key":"B35","first-page":"3839","article-title":"The application value of oXiris-endotoxin adsorption in sepsis","volume":"13","author":"Zhai","year":"2021","journal-title":"Am J Transl Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.accpm.2018.02.024","article-title":"Impact of connecting continuous renal replacement therapy to the extracorporeal membrane oxygenation circuit","volume":"37","author":"de Tymowski","year":"2018","journal-title":"Anaesthesia Crit Care Pain Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.738496\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T10:02:05Z","timestamp":1644919325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.738496\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2021.738496"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.738496","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"article-number":"738496"}}